Saikinso, Provider of Gut Flora Test "Mykinso," Completes Series D Funding Round with 2nd Close of Series D Extension Round
NQ Score
41/100
N1 Content Completeness
4
AI Summary (NQ-processed)
Saikinso, which develops and provides the gut flora test "Mykinso," has completed its Series D funding round through a third-party allotment of shares as the 2nd close of its Series D extension round. Inno Associates Co., Ltd. has become the lead shareholder, and the company aims to accelerate its efforts towards "primary prevention" and expand personalized solutions by leveraging gut microbiome data and lifestyle data.